Mohammed Y Al-Marrawi

Suggest Changes
Learn More
4555 Background: In mRCC pts who fail first-line VEGF-targeted therapy, there are no available randomized data comparing active drugs. Currently, many clinicians choose a second-line VEGF-targeted(More)
  • 1